Nalfurafine
CAS: 152657-84-6
Ref. TM-T41284
1mg | Ausgelaufen | ||
2mg | Ausgelaufen | ||
5mg | Ausgelaufen | ||
10mg | Ausgelaufen | ||
25mg | Ausgelaufen | ||
50mg | Ausgelaufen | ||
100mg | Ausgelaufen | ||
1ml*10 (DMSO) | Ausgelaufen |
Produktinformation
- TRK-820
- (2E)-N-[(5alpha,6beta)-17-(cyclopropylmethyl)-3,14-dihydroxy-4,5-epoxymorphinan-6-yl]-3-furan-3-yl-N-methylprop-2-enamide
- (2E)-N-[(5α,6β)-17-(Cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-2-propenamide
- (E)-N-(17-(cyclopropylmethyl)-4,5alpha-epoxy-3,14-dihydroxymorphinan-6beta-yl)-3-(furan-3-yl)-N-methylprop-2-enamide
- 2-Propenamide, N-[(5α,6β)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-, (2E)-
- 2-Propenamide, N-[(5α,6β)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-, (E)-
- 2-propenamide, N-[(5alpha,6beta)-17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinan-6-yl]-3-(3-furanyl)-N-methyl-, (2E)-
- Morphinan, 2-propenamide deriv.
Nalfurafine (TRK-820) is an effective and selective agonist of G protein-biased κ-opioid receptor with high translational potential. Nalfurafine enhances the therapeutic potential of MOR-targeting analgesics and can be used for uremic pruritis treatment studies.